New drug batoclimab shows promise for Hard-to-Treat Graves' disease
NCT ID NCT05907668
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called batoclimab in 35 adults with Graves' disease whose thyroid hormone levels were still high despite taking standard antithyroid drugs. The goal was to see if batoclimab could help bring those levels back to normal or below over 24 weeks. Batoclimab works by blocking a protein that affects the immune system's attack on the thyroid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
batoclimab
What this could lead to
If successful, batoclimab could offer a new treatment option for people with Graves' disease whose thyroid levels remain high despite standard therapy.
What could go wrong
This is a small, early-phase proof-of-concept study with only 35 participants. It may not show clear benefit, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site Number - 6505
Mainz, 55131, Germany